+

WO1993016717A1 - Method and agents for promoting wound healing - Google Patents

Method and agents for promoting wound healing Download PDF

Info

Publication number
WO1993016717A1
WO1993016717A1 PCT/US1993/001677 US9301677W WO9316717A1 WO 1993016717 A1 WO1993016717 A1 WO 1993016717A1 US 9301677 W US9301677 W US 9301677W WO 9316717 A1 WO9316717 A1 WO 9316717A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
group
mixtures
wound healing
advanced glycosylation
Prior art date
Application number
PCT/US1993/001677
Other languages
French (fr)
Inventor
Michael A. Yamin
Veronica M. Ruszala-Mallon
Anthony Cerami
Original Assignee
The Rockefeller University
Alteon Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Rockefeller University, Alteon Inc. filed Critical The Rockefeller University
Publication of WO1993016717A1 publication Critical patent/WO1993016717A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Definitions

  • the present invention generally relates to the repair of damaged tissues in animals and particularly humans, and, more particularly, to the modulation of the healing of wounds in such tissue.
  • tissue wounds occurs from an endless variety • of pathological and non-pathological causes.
  • a variety of cells have been determined to cooperate to repair the damaged tissue and heal the wound.
  • Cells resident in the local tissue participate, as do circulating blood cells specifically recruited into the wound itself and the area nearby.
  • Dramatic changes in cellular function are required by both the resident and recruited cells in order to initiate, coordinate, and sustain the complex process of wound healing. Damaged cells and disrupted tissue matrix must be removed, new cells must be formed, and must grow and mature to replace those lost.
  • the tissue matrix must be resynthesized and remodeled, and even the microvasculature may need to be rebuilt to supply the new tissue.
  • AGEs advanced glycosylation endproducts
  • reducing sugars e.g., glucose
  • protein amino groups react non-enzymatically with protein amino groups to form a diverse series of protein bound moieties with fluorescent and crosslinking properties.
  • These compounds have been implicated in structural and functional alteration of proteins during aging and in certain diseases that are considered degradative and undesirable, e.g., the embrittlement of structural proteins observed in long-term diabetes.
  • AGEs have been identified on the basis of de novo synthesis and tissue isolation procedures.
  • diagnostic and therapeutic protocols are proposed that are predicated in part on the discovery that advanced glycosylation endproducts (AGEs) and other agents previously described for the promotion of the vivo recognition and removal of AGEs, possess a definitive modulating effect upon the progression of tissue reconstruction and wound healing in mammals, and are capable of stimulating and promoting both activities.
  • AGEs advanced glycosylation endproducts
  • the present invention relates in its broadest aspect to the treatment of wounds as well as various wound healing dysfunctions by the administration of a wound healing modulator comprising a material selected from the group consisting of agents capable of modulating wound healing, binding partners thereto, and the muteins and fragments thereof, wherein the agents are selected from advanced glycosylation endproducts (AGEs), compositions and complexes containing advanced glycosylation endproducts alone or bound to a carrier, derivatives thereof, and mixtures thereof.
  • the carrier may include a material selected from carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
  • the agent could include other advanced glycosylation endproducts that may be prepared synthetically or from the reaction between sugars and other macromolecules, and monokines which stimulate phagocytic cells to increase their activity toward advanced glycosylation endproducts.
  • the agent may comprise the compounds FFI or AFGP bound to a protein such as albumin.
  • the agent may comprise a synthetically derived advanced glycosylation endproduct which is prepared, for example, by the reaction of glucose or glucose-6-phosphate with albumin. This reaction product can be used alone or with a carrier in the same fashion as the FF1- albumin complex.
  • a monokine that functions as an agent comprises the protein known as Tumor Necrosis Factor (TNF) and its variant discovered and isolated by one of the inventors herein and named "cachectin". This material may be administered alone or in conjunction with other agents.
  • TNF Tumor Necrosis Factor
  • the agents of the present invention may be administered in conjunction with materials identified hereinafter as "co-stimulatory" agents.
  • co-stimulatory agents include monokines such as lnterleukin-1 (IL-1 ) and gamma-interferon.
  • AGEs useful in accordance herewith may be introduced to particular tissues by injection to stimulate and promote cellular growth or regrowth, in some instances, that will result in the structural and functional enhancement of the treated tissues.
  • the growth stimulating effect of the modulators of the invention finds a further application in the promotion of tissue acceptance and the corresponding limitation or inhibition of tissue rejection in tissue transplantation and reconstruction.
  • fibers implanted to promote tissue regrowth, transplanted organs or synthetic organs prepared in some instances, at least in part from structural proteinaceous material such as collagen may have applied to them one or more of the present wound healing modulators before implantation, to promote acceptance of the exogenous material and incorporation into the target tissue.
  • the modulators in this instance may be bound to the protein or may be otherwise adherently applied as a coating by known techniques. Accordingly, the invention extends to the corresponding prosthetic materials having the modulators applied as a coating thereto, or chemically linked by known methods such as for example, coupling thereto a synthetic AGE such as FFI-BSA or the like.
  • modulators of the present invention derives from the observations presented below, that the application of the wound healing modulator to skin stimulates hair growth. It is apparent from this that the stimulation of hair growth may be achieved by the topical or intradermal application of the present modulators, and the present invention accordingly extends to a method of stimulating hair growth thereby.
  • This method may comprise the local application of the modulator to the dermal area, with the formulation of the modulator dosage contemplating both topical applications and if appropriate, dermal implants or injections.
  • the AGEs that may serve as agents may comprise the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose and ribose; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
  • the agent may comprise an advanced glycosylation endproduct selected from the group consisting of the chromophores 2-(2-furoyl)-4(5)-(2-furanyl)-1 H_-imidazole (FFI), 1 -alkyl-2-formyl-3,4-diglycosyl-pyrrole (AFGP), alone and coupled to carriers such as BSA, HSA, and avidin.
  • Suitable agents also include materials capable of promoting agent production and/or activity, and materials capable of mimicking agent activity, such as homologous agents derived synthetically or from other cellular sources or from other species.
  • the agent binding partners contemplated by the invention include anti-agent antibodies, receptors for the agents, materials not antibodies that antagonize the production and/or wound healing modulating activity of the agents, binding partners thereto, and other binding partners thereof.
  • the present wound healing modulators may comprise materials that are capable of acting in vivo, and in a further embodiment, may be promoters of wound healing.
  • the invention accordingly includes a method for promoting wound healing comprising administering an effective amount of one of the above wound healing modulators individually, or in mixture with each other or formulated as a pharmaceutical composition.
  • the modulators contemplated for use in this method comprise those agents and binding partners that act as promoters of wound healing, and extend for example, to homologous agents derived from other cellular sources or from other species, materials capable of promoting agent production and/or activity, and materials capable of mimicking agent activity.
  • compositions may be prepared in accordance with the invention and comprise therapeutically effective amounts of the present wound healing modulators, either alone or in admixture with each other, and a pharmaceutically acceptable diluent or carrier.
  • the modulators may preferably be present in amounts effective to deliver at least 100 ng/cm 2 and preferably from about 1 ⁇ gfcm 2 to about 10 g/cm 2 thereof.
  • the therapeutic methods of the present invention apply generally to mammals and contemplate veterinary use as well as application to humans.
  • the particular therapeutic protocols will vary accordingly upon the subject of treatment.
  • the present invention contemplates a method for measuring the activity of the wound healing modulators of the present invention.
  • the method comprises retrieving a sample of wound fluid which such disorder is suspected, and incubating the sample with a quantity of a wound healing modulator of the present invention bearing an appropriate detectable label.
  • the sample may thereafter be examined to determine whether such aberrant cellular activity is due to a deficiency in wound healing factor presence or activity, and to thereby attempt to isolate and identify the cause of such disorder.
  • the present invention may also extend to appropriate new drug assays and test kits including the wound healing modulators of the present invention. Accordingly, it is a principal object of the present invention to provide a method for treating wound healing dysfunctions in mammals.
  • compositions for use in therapeutic methods for treating wound healing dysfunctions and/or promoting wound healing which comprise or are based upon certain wound healing modulators including agents and their binding partner(s).
  • wound healing modulator refers to protein material having the profile of activities set forth herein and in the Claims.
  • AGE and “AGEs” are used as appropriate to refer to advanced glycosylation endproducts which are in the form of stable compounds and intermediates which are produced synthetically, ]n vivo, and ]n vitro by the reaction of reducing sugars with protein amino groups. AGEs therefore encompass intermediates as well as stable endproducts that are implicated in the structural and functional alteration of proteins seen during aging. For example, AGEs are recognized to react with free polypeptide amino groups, which leads to protein crosslinking. Additionally, such AGES are observed in elevated levels in circulation and in tissues in certain diseases, e.g. diabetes mellitus.
  • AGE-RNAse refers to the advanced glycosylation endproducts which are formed upon chemical reaction of the substrates RNAse, Hb, BSA, HSA, albumin, collagen and LDL, respectively with a reducing sugar.
  • AGE-RNAse refers to the advanced glycosylation endproducts of the reaction between bovine ribonuclease and a reducing sugar.
  • Albumin when recited generically, refers to any species from which it was obtained, e.g., human, bovine, etc.
  • BSA refers to bovine serum albumin.
  • HSA refers to human serum albumin.
  • RNAse refers to ribonuclease generally, and where appropriate, to bovine pancreatic ribonuclease in particular.
  • Collagen is used in the conventional sense to refer to any type of collagen and derived from any appropriate source. When a specific type of collagen was used, such as in the example, the particular type is noted. However, it is recognized that alternative collagen types can also be used.
  • FFI-BSA refers to a model AGE-protein produced by mixing 2-(2-furoyl)-4(5)J2-furanyl)-1 H_-imidazole hexanoic acid with bovine serum albumin and coupling the reactive compounds with dicyclohexylcarbodiimide.
  • proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of these materials. Also, the terms "wound healing modulator” and “agent” are intended where appropriate, to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.
  • an “antibody” is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope.
  • the term encompasses, inter alia, polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,81 6,397 and 4,816,567.
  • phrases “pharmaceutically acceptable” refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
  • terapéuticaally effective amount is used herein in the qualitative sense to mean an amount sufficient to promote the healing of a non-healing wound. Quantitatively, this phrase means an amount sufficient to promote, and preferably accelerate by at least about 10 percent, more preferably by at least 20 percent, a clinically significant change in the rate or extent of wound healing as a result of the administration of the wound healing modulator of the present invention.
  • the present invention concerns methods of diagnosing and treating wound healing dysfunction by resort to the identification and administration of certain modulators of wound healing, including certain agents represented in part by a class of compounds known as advanced glycosylation endproducts (AGEs) that are believed to take part in the promotion of wound healing.
  • AGEs advanced glycosylation endproducts
  • the present invention includes therapeutic methods employing the wound healing modulators identified herein and compositions containing the same for use in such methods.
  • the wound healing modulators of the present invention comprising the agents, their homologs, similarly active drugs, their receptors, their binding partner(s) or other ligands or agents exhibiting either mimicry or antagonism to the agents or control over their production, may be prepared in pharmaceutical compositions, with a suitable carrier and at a strength effective for administration by various means to a patient having a tissue wound or a wound healing disorder or dysfunction, for the treatment thereof.
  • compositions may be administered by parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, including delivery in an irrigation fluid used to wash body wound areas, catheterizations and the like.
  • parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, including delivery in an irrigation fluid used to wash body wound areas, catheterizations and the like.
  • Average quantities of the wound healing modulator may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian.
  • concentrations of the wound healing modulator may range from at least about 100 ng/cm 2 , and preferably from about 1 /g/cm 2 to about 10 ⁇ g/cm 2 may be used.
  • concentrations of the wound healing modulator administered may vary and should be based upon the recommendations and prescription of a qualified physician or veterinarian.
  • the materials that function as modulators of wound healing extend to the binding partners of the agents defined herein, and particularly include the antibodies, receptors, materials not antibodies to the agents that antagonize the production and/or wound healing modulating activity of the agents and other binding partners thereto.
  • certain agents such as AGE-RNAse
  • specific antibodies that would antagonize the modulating effect that they exert on wound healing could be identified.
  • Antibodies including both polyclonal and monoclonal antibodies, and drugs may also be raised to the agent and may be utilized where appropriate for the purpose of modulating wound healing by a mammalian host.
  • the agent may be used to produce antibodies to itself in a variety of animals, by known techniques such as the hybridoma technique utilizing, for example, fused mouse spleen lymphocytes and myeloma cells.
  • the resulting antibodies could then be prepared in a suitable pharmaceutical composition and administered to the intended host.
  • the exact quantities, intervals of administration and administrative techniques respecting such pharmaceutical compositions may vary in accordance with those known in the medical arts, and upon the specific instruction of a qualified physician or veterinarian.
  • the agents may bind to particular naturally occurring binding activities including cell associated and soluble receptors to facilitate intracellular transmission of messages relating to wound healing activity, and these binding activities or receptor molecules may be identified as they form complexes with the agents, and thereafter may be isolated and prepared in sufficient quantities to be used in the same fashion as the agents themselves, to modulate wound healing activity.
  • binding activities or receptor molecules may be identified as they form complexes with the agents, and thereafter may be isolated and prepared in sufficient quantities to be used in the same fashion as the agents themselves, to modulate wound healing activity.
  • a variety of diverse receptor systems are known, such as the tyrosine kinases and G-protein receptors are already known and operate to transmit messages to the genetic material of the cell to cause corresponding changes in protein synthesis, and the present invention contemplates that these molecules and other functionally similar molecules, may participate in wound healing modulation in accordance herewith.
  • the present invention also relates to a variety of diagnostic applications, including methods for detecting or investigating disorders or dysfunctions in wound healing by reference to the ability of the present wound healing modulators of the present invention comprising the agents and their binding partners to promote or inhibit wound healing activity.
  • the agents or their binding partners could be appropriately labeled and placed in contact with a sample of wound inflammatory fluid, tissue or blood from a mammal in which the disorder is suspected. Thereafter, the sample could be examined to determine the location and status of the labeled material as well as the general activity of the sample, i.e. whether wound healing activity has increased or decreased.
  • Solutions of purified AGE-collagen and collagen alone were prepared in vehicle from concentrated stocks (below) to the desired final concentrations. A 50 ⁇ drop of AGE-collagen- or collagen-vehicle or vehicle alone was applied to each wound, and spread over the wound with the tip of a sterile pipette.
  • Wounds were individually sealed with a semipermeable dressing: Benzoin was applied as an adhesive to a zone of intact skin surrounding the perimeter of each wound and the wound was sealed with a patch of Opsite applied to cover the wound and extend over and adhere to the zone of Benzoin-treated intact skin surrounding each wound. Ops ⁇ te-sealed wounds were then covered with a bulky dressing.
  • Biopsies of healing wounds were initially taken on days 3, 4 and 5 after wounding. Preliminary analysis of control wounds revealed that day 4 wounds were best suited to display differences in the rate or degree of healing, and day 4 biopsies were obtained from subsequent tests. Control wounds on day 4 typically show mild residual inflammation and fibroblast activity with persisting ulceration in the sense that epidermal regrowth is still incomplete and portions of the dermis remain exposed. Where epidermis is reforming from the margins of the wound and focally from the hair follicles spared by wounding, there is good granular layer formation with areas of overlying cornified epithelium and little parakeratosis. At this incompletely healed stage, then, a variety of histological characteristics of wound healing are intermediate.
  • Acceleration or retardation of wound healing is manifest to a trained dermatopathologist by light microscopic comparison of histological sections prepared from biopsies of the healing wounds. Histological sections from wounds in which healing has been accelerated by treatment can be expected to have less remaining ulceration or even complete recoverage by epidermis with good granular layer formation and a more complete overlying cornified layer, and little or no residual fibroblast proliferation or parakeratosis. These histological criteria for completeness of healing can be expected to vary in the other direction if wound healing is retarded by treatment.
  • test pigs were anesthetized as at wounding, wound dressings were removed, and the wounds photographed for gross characterization of healing. When fully anesthetized, test pigs were then overdosed with SleepAway euthanasia solution. Elliptical biopsy samples through the full skin thickness (into the layer of subcutaneous fat) and extending across the full width of the wound and into intact skin on either side were then cut from each wound by hand using a scalpel. Biopsy samples were individually fixed by immersion in 10% buffered formalin in coded containers which did not reveal what treatment the parent wound had received.
  • Coded samples were then routinely processed for light microscopic histological analysis by sectioning at 5 ⁇ m, mounting on slides, and staining with hematoxyiin and eosin.
  • the biopsies were cut into histological sections in a plane normal (perpendicular) to the surface of the skin, so as to include both the full extent of the wound and a small margin of non-wounded skin at each end of the section.
  • the degree of wound healing was assessed by measuring the linear extent of re- epithelialization across the full width of the histological sections from the wound biopsy; that is, from the boundary of non-wounded skin on one side of the section to the boundary of non-wounded skin at the other side of the wound.
  • Measurements were taken microscopically, by using a calibrated ocular reticule to measure the linear extent of the total wound, and the linear extent of re- epithelial ⁇ zed wound.
  • the linear extent of re-epithel ⁇ alized wound was then expressed as a percentage of the linear extent of the total wound, and this percentage was taken as a measurement of the degree of wound healing.
  • the sections taken 3 days after healing show a marked difference between tissue treated with AGE-collagen and that treated with unmodified collagen.
  • the treated tissue shows completely healed epidermis, with full epithelialization overlying a slightly cellular dermis.
  • the epidermis shows focally a good granular layer, and only minimal parakeratosis.
  • the control tissue while fully epithelialized, still contains many fibroblasts within the dermis, and there is only poor granular layer formation. This suggests a much less advanced healing wound. Similar changes are seen in tissue taken 4 and 5 days post wounding.
  • the tissue treated with AGE-coilagen consistently shows more mature appearing epidermis, with full granular and minimal overlying parakeratosis.
  • the control sections, while almost completely epithelialized still show poor granular layer formation and extensive overlying parakeratosis.
  • mice Male Lewis rats (350-450 g) were made diabetic by intravenous injection of streptozotocin (65 mg/kg). One week later, they were bled, and their plasma tested for glucose levels. Rats with glucose levels greater than 400 mg/dl were considered diabetic. Diabetic and non-diabetic rats were then divided into groups:
  • the rats were anesthetized using a mixture of Xylazine and Ketamine (1 :9), given intramuscularly at a level of .001 mg/g body weight.
  • the backs of the rats were shaved, washed with soap and water, sprayed with alcohol, and swabbed with Provadine.
  • An incision of approximately 5 cm was made in the skin along the midline of the back.
  • a subcutaneous continuous stitch was used to close the incision, using the appropriate suture lot.
  • the incision sites were visually inspected on a daily basis to monitor healing.
  • the animals were sacrificed at 14 days using C0 2 .
  • the skin from their backs was removed, and evaluated visually as to how they have healed in comparison with the control groups.
  • the extent of wound closure was evaluated, blinded to group, by three individuals and graded on a scale of 1 + to 3+ with 1 + being the least healed and 3 + being the best closure with little or no scar.
  • the degree of vascularization was evaluated by examination of the underlying skin using a light box. This enabled the investigator to visualize by transmitted light the amount of blood vessels formed along the suture line.
  • Vascularity was evaluated on a 1 + to 4+ scale with 1 + being little vascularity around the incision site and 4 + being the greatest degree of vascularity. All animals were coded so that the final evaluations were done blinded as to the treatment group.
  • Rat # F had some pus oozing from incision TABLE C
  • mice 25 non-diabetic male C 3 H/Hej mice (25-30g) were anesthetized as described above. Their backs were shaved, washed with soap and water, sprayed with alcohol, and swabbed with Provadine. An incision of approximately 2-2.5 cm was made in the skin along the midline of the back. A cutaneous interrupted stitch was used to close the incision, using either control silk sutures or AGE-silk sutures (incubated with ribose as described in Example 2). The animals were sacrificed 7 days later and the skin removed as described above. The closure could not be evaluated adequately in mice due to the thin nature of the skin and the dark color of the strain being tested. Therefore, only the degree of vascularity was assessed as described above. One obvious but unexpected occurrence in this study was related to the degree of new hair growth in mice whose wounds were closed using AGE sutures. These results are included in Table D, below. TABLE D
  • the agents herein may be formulated for the treatment of a variety of mammals, including domestic and farm animals, as well as humans, to control the wound healing process, and where desired, to assist in its promotion and the promotion of tissue growth and reconstruction as described and as evidenced hereinabove.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the promotion of tissue turnover by the administration of one or more wound healing modulators. The wound healing modulator may be selected from appropriate wound healing agents and binding partners, and particularly agents that enhance wound healing. The agent may comprise advanced glycosylation endproducts (AGEs), compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof. The AGEs constituting agents may particularly comprise the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose and ribose; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof. Diagnostic and therapeutic utilities are proposed, the latter including the treatment of wound healing dysfunction, the promotion of transplant tissue acceptance and the promotion of hair growth. Pharmaceutical compositions and prosthetic materials are likewise contemplated and set forth.

Description

METHOD AND AGENTS FOR PROMOTING WOUND HEALING
RELATED PUBLICATIONS
The Applicants are co-authors of the following articles directed to the subject matter of the present invention:
"FUNCTION OF MACROPHAGE RECEPTOR FOR NONENZYMATICALLY GLYCOSYLATED PROTEINS IS MODULATED BY INSUUMJLΕVELS", Vlassara, Brownlee and Cerami, DIABETES (1986), Vol. 35 Supp. 1 , Page 13a; "ACCUMULATION OF DIABETIC RAT PERIPHERAL NERVE MYELIN BY MACROPHAGES INCREASES WITH THE PRESENCE OF ADVANCED GLYCOSYLATION ENDPRODUCTS", Vlassara, H., Brownlee, M., and Cerami, A. J. EXP. MED. (1984), Vol. 1 60, pp. 197-207; "RECOGNITION AND UPTAKE OF HUMAN DIABETIC PERIPHERAL NERVE MYELIN BY MACROPHAGES", Vlassara, H., Brownlee, M., and Cerami, A. DIABETES (1985), Vol. 34, No. 6, pp. 553- 557; "HIGH-AFFINITY-RECEPTOR-MEDIATED UPTAKE AND DEGRADATION OF GLUCOSE-MODIFIED PROTEINS: A POTENTIAL MECHANISM FOR THE REMOVAL OF SENESCENT MACROMOLECULES", Vlassara H., Brownlee, M., and Cerami, A., PROC. NATL. ACAD. SCI. U.S.A. (Sept. 1985), Vol. 82, pp. 5588-5592; "NOVEL MACROPHAGE RECEPTOR FOR GLUCOSE-MODIFIED PROTEINS IS DISTINCT FROM PREVIOUSLY DESCRIBED SCAVENGER RECEPTORS", Vlassara, H., Brownlee, M., and Cerami, A. JOUR. EXP. MED. (1986), Vol. 164, pp. 1301 -1309; "ROLE OF NONENZYMATIC GLYCOSYLATION IN ATHEROGENESIS", Cerami, A., Vlassara, H., and Brownlee, M., JOURNAL OF CELLULAR BIOCHEMISTRY (1986), Vol. 30, pp. 1 1 1-120; "CHARACTERIZATION OF A SOLUBILIZED CELL SURFACE BINDING PROTEIN ON MACROPHAGES SPECIFIC FOR PROTEINS MODIFIED NONENZYMATICALLY BY ADVANCED GLYCOSYLATION END PRODUCTS", Radoff, S., Vlassara, H. and Cerami, A., ARCH. BIOCHEM. BIOPHYS (1988), Vol. 263, No. 2, pp. 41 8-423; "ISOLATION OF A SURFACE BINDING PROTEIN SPECIFIC FOR ADVANCED GLYCOSYLATION ENDPRODUCTS FROM THE MURINE MACROPHAGE-DERIVED CELL LINE RAW 264.7", Radoff, S., Vlassara, H., and Cerami, A., DIABETES, (1990), Vol. 39, pp. 1510-1 518. All of the foregoing publications are incorporated herein by reference. BACKGROUND OF THE INVENTION
The present invention generally relates to the repair of damaged tissues in animals and particularly humans, and, more particularly, to the modulation of the healing of wounds in such tissue.
Injury to animal tissue resulting in tissue wounds occurs from an endless variety of pathological and non-pathological causes. In response to injury, a variety of cells have been determined to cooperate to repair the damaged tissue and heal the wound. Cells resident in the local tissue participate, as do circulating blood cells specifically recruited into the wound itself and the area nearby. Dramatic changes in cellular function are required by both the resident and recruited cells in order to initiate, coordinate, and sustain the complex process of wound healing. Damaged cells and disrupted tissue matrix must be removed, new cells must be formed, and must grow and mature to replace those lost. The tissue matrix must be resynthesized and remodeled, and even the microvasculature may need to be rebuilt to supply the new tissue.
It is now recognized that cytokines exchanged among responding cells mediate the induction, control, and coordination of these and other cellular functions necessary to successfully heal the wound.
Recent interest and study of advanced glycosylation endproducts ("AGEs") has developed, and began with the observation that reducing sugars, e.g., glucose, react non-enzymatically with protein amino groups to form a diverse series of protein bound moieties with fluorescent and crosslinking properties. These compounds have been implicated in structural and functional alteration of proteins during aging and in certain diseases that are considered degradative and undesirable, e.g., the embrittlement of structural proteins observed in long-term diabetes. Several AGEs have been identified on the basis of de novo synthesis and tissue isolation procedures.
In Parent Application Serial No. 907,747 and in applications following therefrom, the use of AGEs and other agents for the recognition and removal of jn vivo resident advanced glycosylation endproducts was disclosed. The admipinstration of these agents, however, was for the essentially catabolic purpose of mobilizing the macrophage to recognize and remove AGEs. Since AGEs accumulate in pathological states, it was not apparent what role AGEs might play in the promotion and facilitation of wound healing. It is therefore to this determination and other discoveries that the present Application is directed.
SUMMARY OF THE INVENTION
In accordance with the present invention, diagnostic and therapeutic protocols are proposed that are predicated in part on the discovery that advanced glycosylation endproducts (AGEs) and other agents previously described for the promotion of the vivo recognition and removal of AGEs, possess a definitive modulating effect upon the progression of tissue reconstruction and wound healing in mammals, and are capable of stimulating and promoting both activities.
Accordingly, the present invention relates in its broadest aspect to the treatment of wounds as well as various wound healing dysfunctions by the administration of a wound healing modulator comprising a material selected from the group consisting of agents capable of modulating wound healing, binding partners thereto, and the muteins and fragments thereof, wherein the agents are selected from advanced glycosylation endproducts (AGEs), compositions and complexes containing advanced glycosylation endproducts alone or bound to a carrier, derivatives thereof, and mixtures thereof. The carrier may include a material selected from carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof. The agent could include other advanced glycosylation endproducts that may be prepared synthetically or from the reaction between sugars and other macromolecules, and monokines which stimulate phagocytic cells to increase their activity toward advanced glycosylation endproducts.
Accordingly, the agent may comprise the compounds FFI or AFGP bound to a protein such as albumin. Alternately, the agent may comprise a synthetically derived advanced glycosylation endproduct which is prepared, for example, by the reaction of glucose or glucose-6-phosphate with albumin. This reaction product can be used alone or with a carrier in the same fashion as the FF1- albumin complex.
A monokine that functions as an agent comprises the protein known as Tumor Necrosis Factor (TNF) and its variant discovered and isolated by one of the inventors herein and named "cachectin". This material may be administered alone or in conjunction with other agents.
In addition, the agents of the present invention may be administered in conjunction with materials identified hereinafter as "co-stimulatory" agents. The coadmϊnistration of the agent with the co-stimulatory agents has been found to potentiate the activity of the former. Suitable co-stimulatory agents include monokines such as lnterleukin-1 (IL-1 ) and gamma-interferon.
Particular therapeutic applications contemplate the administration of the wound healing modulators to specific tissues and organs to promote tissue remodelling and reconstruction. For example, AGEs useful in accordance herewith may be introduced to particular tissues by injection to stimulate and promote cellular growth or regrowth, in some instances, that will result in the structural and functional enhancement of the treated tissues.
The growth stimulating effect of the modulators of the invention finds a further application in the promotion of tissue acceptance and the corresponding limitation or inhibition of tissue rejection in tissue transplantation and reconstruction. For example, fibers implanted to promote tissue regrowth, transplanted organs or synthetic organs prepared in some instances, at least in part from structural proteinaceous material such as collagen, may have applied to them one or more of the present wound healing modulators before implantation, to promote acceptance of the exogenous material and incorporation into the target tissue. The modulators in this instance may be bound to the protein or may be otherwise adherently applied as a coating by known techniques. Accordingly, the invention extends to the corresponding prosthetic materials having the modulators applied as a coating thereto, or chemically linked by known methods such as for example, coupling thereto a synthetic AGE such as FFI-BSA or the like.
Another application of the modulators of the present invention derives from the observations presented below, that the application of the wound healing modulator to skin stimulates hair growth. It is apparent from this that the stimulation of hair growth may be achieved by the topical or intradermal application of the present modulators, and the present invention accordingly extends to a method of stimulating hair growth thereby. This method may comprise the local application of the modulator to the dermal area, with the formulation of the modulator dosage contemplating both topical applications and if appropriate, dermal implants or injections.
The AGEs that may serve as agents may comprise the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose and ribose; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof. Particularly, the agent may comprise an advanced glycosylation endproduct selected from the group consisting of the chromophores 2-(2-furoyl)-4(5)-(2-furanyl)-1 H_-imidazole (FFI), 1 -alkyl-2-formyl-3,4-diglycosyl-pyrrole (AFGP), alone and coupled to carriers such as BSA, HSA, and avidin.
Suitable agents also include materials capable of promoting agent production and/or activity, and materials capable of mimicking agent activity, such as homologous agents derived synthetically or from other cellular sources or from other species. The agent binding partners contemplated by the invention include anti-agent antibodies, receptors for the agents, materials not antibodies that antagonize the production and/or wound healing modulating activity of the agents, binding partners thereto, and other binding partners thereof. The present wound healing modulators may comprise materials that are capable of acting in vivo, and in a further embodiment, may be promoters of wound healing. The invention accordingly includes a method for promoting wound healing comprising administering an effective amount of one of the above wound healing modulators individually, or in mixture with each other or formulated as a pharmaceutical composition. More particularly, the modulators contemplated for use in this method comprise those agents and binding partners that act as promoters of wound healing, and extend for example, to homologous agents derived from other cellular sources or from other species, materials capable of promoting agent production and/or activity, and materials capable of mimicking agent activity.
Pharmaceutical compositions may be prepared in accordance with the invention and comprise therapeutically effective amounts of the present wound healing modulators, either alone or in admixture with each other, and a pharmaceutically acceptable diluent or carrier. The modulators may preferably be present in amounts effective to deliver at least 100 ng/cm2 and preferably from about 1 μgfcm2 to about 10 g/cm2 thereof.
The therapeutic methods of the present invention apply generally to mammals and contemplate veterinary use as well as application to humans. The particular therapeutic protocols will vary accordingly upon the subject of treatment.
In the instance where wound healing may be beneficially monitored, such as to identify suspected disorders affecting wound healing, the present invention contemplates a method for measuring the activity of the wound healing modulators of the present invention. The method comprises retrieving a sample of wound fluid which such disorder is suspected, and incubating the sample with a quantity of a wound healing modulator of the present invention bearing an appropriate detectable label. The sample may thereafter be examined to determine whether such aberrant cellular activity is due to a deficiency in wound healing factor presence or activity, and to thereby attempt to isolate and identify the cause of such disorder. The present invention may also extend to appropriate new drug assays and test kits including the wound healing modulators of the present invention. Accordingly, it is a principal object of the present invention to provide a method for treating wound healing dysfunctions in mammals.
It is a further object of the present invention to provide a method as aforesaid that is applicable to the promotion of tissue turnover and wound healing.
It is a yet further object of the present invention to provide pharmaceutical compositions for use in therapeutic methods for treating wound healing dysfunctions and/or promoting wound healing which comprise or are based upon certain wound healing modulators including agents and their binding partner(s).
It is a still further object of the present invention to provide a method for promoting wound healing by the administration of the pharmaceutical composition as aforesaid.
It is a still further object of the present invention to provide a method for promoting hair growth by the topical application of the modulators of the present invention as aforesaid.
It is a still further object of the present invention to provide a method for promoting implant acceptance and incorporation by the application to the implant material prior to implantation of the wound healing modulators as aforesaid.
It is a further object of the present invention to provide a method for measuring the activity of the wound healing modulators as aforesaid, that also serves to evaluate possible disorders in wound healing.
Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing description. DETAILED DESCRIPTION
In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. Therefore, if appearing herein, the following terms shall have the definitions set out below. The term "stimulus" and its plural as used herein are intended to apply to invasive events such as infection, as well as conditions caused by wounding, and to idiopathϊc or spontaneous states that may for example, originate from cellular or metabolic derangements or other causes.
The terms "wound healing modulator", "agent", "AGE" and "AGEs" as used throughout the present application and claims refer to protein material having the profile of activities set forth herein and in the Claims. The terms "AGE" and "AGEs" are used as appropriate to refer to advanced glycosylation endproducts which are in the form of stable compounds and intermediates which are produced synthetically, ]n vivo, and ]n vitro by the reaction of reducing sugars with protein amino groups. AGEs therefore encompass intermediates as well as stable endproducts that are implicated in the structural and functional alteration of proteins seen during aging. For example, AGEs are recognized to react with free polypeptide amino groups, which leads to protein crosslinking. Additionally, such AGES are observed in elevated levels in circulation and in tissues in certain diseases, e.g. diabetes mellitus.
When the designations "AGE-RNAse", "AGE-Hb", "AGE-BSA", "AGE-HSA", "AGE-albumin", "AGE-coIlagen" and "AGE-LDL" are used, each refers to the advanced glycosylation endproducts which are formed upon chemical reaction of the substrates RNAse, Hb, BSA, HSA, albumin, collagen and LDL, respectively with a reducing sugar. Thus, AGE-RNAse refers to the advanced glycosylation endproducts of the reaction between bovine ribonuclease and a reducing sugar.
Albumin, when recited generically, refers to any species from which it was obtained, e.g., human, bovine, etc. BSA refers to bovine serum albumin.
HSA refers to human serum albumin.
RNAse refers to ribonuclease generally, and where appropriate, to bovine pancreatic ribonuclease in particular.
Collagen is used in the conventional sense to refer to any type of collagen and derived from any appropriate source. When a specific type of collagen was used, such as in the example, the particular type is noted. However, it is recognized that alternative collagen types can also be used.
Where present, the term "FFI-BSA" refers to a model AGE-protein produced by mixing 2-(2-furoyl)-4(5)J2-furanyl)-1 H_-imidazole hexanoic acid with bovine serum albumin and coupling the reactive compounds with dicyclohexylcarbodiimide.
Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of these materials. Also, the terms "wound healing modulator" and "agent" are intended where appropriate, to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.
An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses, inter alia, polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,81 6,397 and 4,816,567.
The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
The phrase "therapeutically effective amount" is used herein in the qualitative sense to mean an amount sufficient to promote the healing of a non-healing wound. Quantitatively, this phrase means an amount sufficient to promote, and preferably accelerate by at least about 10 percent, more preferably by at least 20 percent, a clinically significant change in the rate or extent of wound healing as a result of the administration of the wound healing modulator of the present invention.
In its primary aspect, the present invention concerns methods of diagnosing and treating wound healing dysfunction by resort to the identification and administration of certain modulators of wound healing, including certain agents represented in part by a class of compounds known as advanced glycosylation endproducts (AGEs) that are believed to take part in the promotion of wound healing.
As discussed earlier, the present invention includes therapeutic methods employing the wound healing modulators identified herein and compositions containing the same for use in such methods. Accordingly, the wound healing modulators of the present invention comprising the agents, their homologs, similarly active drugs, their receptors, their binding partner(s) or other ligands or agents exhibiting either mimicry or antagonism to the agents or control over their production, may be prepared in pharmaceutical compositions, with a suitable carrier and at a strength effective for administration by various means to a patient having a tissue wound or a wound healing disorder or dysfunction, for the treatment thereof.
A variety of administrative techniques may be utilized, among them topical applications as in ointments or on surgical and other topical appliances such as, surgical sponges, bandages, gauze pads, and the like. Also, such compositions may be administered by parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, including delivery in an irrigation fluid used to wash body wound areas, catheterizations and the like. Average quantities of the wound healing modulator may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian.
In particular, concentrations of the wound healing modulator may range from at least about 100 ng/cm2, and preferably from about 1 /g/cm2 to about 10 μg/cm2 may be used. The exact quantities of the wound healing modulator administered may vary and should be based upon the recommendations and prescription of a qualified physician or veterinarian.
As mentioned earlier, the materials that function as modulators of wound healing extend to the binding partners of the agents defined herein, and particularly include the antibodies, receptors, materials not antibodies to the agents that antagonize the production and/or wound healing modulating activity of the agents and other binding partners thereto. In the instance of certain agents such as AGE-RNAse, specific antibodies that would antagonize the modulating effect that they exert on wound healing could be identified.
Antibodies, including both polyclonal and monoclonal antibodies, and drugs may also be raised to the agent and may be utilized where appropriate for the purpose of modulating wound healing by a mammalian host. In particular, the agent may be used to produce antibodies to itself in a variety of animals, by known techniques such as the hybridoma technique utilizing, for example, fused mouse spleen lymphocytes and myeloma cells. The resulting antibodies could then be prepared in a suitable pharmaceutical composition and administered to the intended host. The exact quantities, intervals of administration and administrative techniques respecting such pharmaceutical compositions may vary in accordance with those known in the medical arts, and upon the specific instruction of a qualified physician or veterinarian.
Similarly, the agents may bind to particular naturally occurring binding activities including cell associated and soluble receptors to facilitate intracellular transmission of messages relating to wound healing activity, and these binding activities or receptor molecules may be identified as they form complexes with the agents, and thereafter may be isolated and prepared in sufficient quantities to be used in the same fashion as the agents themselves, to modulate wound healing activity. By way of illustration and not limitation, a variety of diverse receptor systems are known, such as the tyrosine kinases and G-protein receptors are already known and operate to transmit messages to the genetic material of the cell to cause corresponding changes in protein synthesis, and the present invention contemplates that these molecules and other functionally similar molecules, may participate in wound healing modulation in accordance herewith.
The present invention also relates to a variety of diagnostic applications, including methods for detecting or investigating disorders or dysfunctions in wound healing by reference to the ability of the present wound healing modulators of the present invention comprising the agents and their binding partners to promote or inhibit wound healing activity. As mentioned earlier, the agents or their binding partners could be appropriately labeled and placed in contact with a sample of wound inflammatory fluid, tissue or blood from a mammal in which the disorder is suspected. Thereafter, the sample could be examined to determine the location and status of the labeled material as well as the general activity of the sample, i.e. whether wound healing activity has increased or decreased.
As indicated earlier, the following examples set forth the details of the investigation and identification of the wound healing promoting activity of the stated inflammatory cytokines. Naturally, the specific materials and techniques set forth hereinafter are exemplary only and may vary, so that the following is presented as illustrative but not restrictive of the present invention.
EXAMPLE 1
Promotion of Wound Healing in vivo bv AGEs
This series of experiments sought to determine whether advanced glycosylation endproducts such as AGE-collagen tested herein were involved in any way in promoting wound healing. Accordingly, AGE-collagen and unmodified collagen were assessed in a standard porcine model of wound healing in response to partial thickness skin injury.
Materials and Methods
Surgical Wounding
The wound healing model used in these studies is a modification of that described by Eaglstein and co-workers ("New Method for Assessing Wound Healing: The Effects of Triamcinolone Acetonide and Polyethylene Film
Occlusion," J. of Invest. Derm.. 71:382-384, 1978). Young White Yorkshire pigs weighing 10-15 kg were used all wounding experiments. Anesthesia was induced in the following manr. Pigs received pre-operative medication with Azaperone (1 mg/lb), Atropine (0.04 mg/kg) and Ketamine (10 mg/kg) by s.m. injection. Animals were then taken to the surgical suite, intut ed and maintained under Isofluorane inhalation anesthesia and re rous oxicu at 1 .5 L/min. The animals w .ι _, liven supplemental oxygen during the procedure and maintained on a warning banket.
Once adequate anesthesia had been attained, the back ar dorsal t A ax of the pigs was shaved and prepared with a 70% alcohol solutiϋ . Tempa.ature was monitored throughout the operation, and an i.v. line (started after the animal was asleep) was maintained. Depth of anesthesia was monitored by corneal reflexes and withdrawal to painful stimuli. Anesthesia was titrated to maintain an unresponsive state. Partial thickness epidermal wounds were then made with a Padgett dermatome to a depth of 0.01 5 inches. Wounds were 2 x 5 cm in area. This type of injury, which removes the epidermis and a zone of the superficial dermis but spares the hair follicles, has been previously shown to be comparable to a second degree burn injury or a donor site for a skin graft.
Once all of the wounds had been created (eight pairs of wounds were made, one wound of each pair on each side of the midline), the wounds were treated and dressed. The animals were then allowed to emerge from anesthesia and monitored closely for pain. Pain was treated with Demerol (10 mg/kg i.m.) every 4-6 hours as needed.
Treatment of Wounds Partial thickness cutaneous wounds were treated in pairs; one wound of each pair was treated with AGE-collagen in vehicle (PBS), the other treated with an amount of collagen alone in vehicle. Wounds were treated in a pattern of bilateral pairs, whereby every AGE-collagen treated wound was matched to a contralaterally corresponding wound treated with collagen alone, at the same location on the other side of the midline of the back.
Solutions of purified AGE-collagen and collagen alone, were prepared in vehicle from concentrated stocks (below) to the desired final concentrations. A 50 μ\ drop of AGE-collagen- or collagen-vehicle or vehicle alone was applied to each wound, and spread over the wound with the tip of a sterile pipette.
Wounds were individually sealed with a semipermeable dressing: Benzoin was applied as an adhesive to a zone of intact skin surrounding the perimeter of each wound and the wound was sealed with a patch of Opsite applied to cover the wound and extend over and adhere to the zone of Benzoin-treated intact skin surrounding each wound. Opsϊte-sealed wounds were then covered with a bulky dressing.
Dosages Wounds were treated with AGE-collagen/collagen at the time of wounding and daily thereafter, at various dosages from 1 to 10 μg AGE-collagen or unmodified collagen per 50 μ\ vehicle (PBS) per wound. Because wounds measured approximately 2 x 5 cm, this dosage corresponds to 0.1 to 1 μg AGE-collagen or unmodified collagen per cm2 wound area, respectively.
Biopsy Technioue and Histolooical Analysis
Biopsies of healing wounds were initially taken on days 3, 4 and 5 after wounding. Preliminary analysis of control wounds revealed that day 4 wounds were best suited to display differences in the rate or degree of healing, and day 4 biopsies were obtained from subsequent tests. Control wounds on day 4 typically show mild residual inflammation and fibroblast activity with persisting ulceration in the sense that epidermal regrowth is still incomplete and portions of the dermis remain exposed. Where epidermis is reforming from the margins of the wound and focally from the hair follicles spared by wounding, there is good granular layer formation with areas of overlying cornified epithelium and little parakeratosis. At this incompletely healed stage, then, a variety of histological characteristics of wound healing are intermediate.
Acceleration or retardation of wound healing is manifest to a trained dermatopathologist by light microscopic comparison of histological sections prepared from biopsies of the healing wounds. Histological sections from wounds in which healing has been accelerated by treatment can be expected to have less remaining ulceration or even complete recoverage by epidermis with good granular layer formation and a more complete overlying cornified layer, and little or no residual fibroblast proliferation or parakeratosis. These histological criteria for completeness of healing can be expected to vary in the other direction if wound healing is retarded by treatment.
To assess the rate and completeness of healing, test pigs were anesthetized as at wounding, wound dressings were removed, and the wounds photographed for gross characterization of healing. When fully anesthetized, test pigs were then overdosed with SleepAway euthanasia solution. Elliptical biopsy samples through the full skin thickness (into the layer of subcutaneous fat) and extending across the full width of the wound and into intact skin on either side were then cut from each wound by hand using a scalpel. Biopsy samples were individually fixed by immersion in 10% buffered formalin in coded containers which did not reveal what treatment the parent wound had received. Coded samples were then routinely processed for light microscopic histological analysis by sectioning at 5 μm, mounting on slides, and staining with hematoxyiin and eosin. The biopsies were cut into histological sections in a plane normal (perpendicular) to the surface of the skin, so as to include both the full extent of the wound and a small margin of non-wounded skin at each end of the section. The degree of wound healing was assessed by measuring the linear extent of re- epithelialization across the full width of the histological sections from the wound biopsy; that is, from the boundary of non-wounded skin on one side of the section to the boundary of non-wounded skin at the other side of the wound. Measurements were taken microscopically, by using a calibrated ocular reticule to measure the linear extent of the total wound, and the linear extent of re- epithelialϊzed wound. The linear extent of re-epithelϊalized wound was then expressed as a percentage of the linear extent of the total wound, and this percentage was taken as a measurement of the degree of wound healing.
RESULTS The sections taken 3 days after healing show a marked difference between tissue treated with AGE-collagen and that treated with unmodified collagen. The treated tissue shows completely healed epidermis, with full epithelialization overlying a slightly cellular dermis. The epidermis shows focally a good granular layer, and only minimal parakeratosis. The control tissue, while fully epithelialized, still contains many fibroblasts within the dermis, and there is only poor granular layer formation. This suggests a much less advanced healing wound. Similar changes are seen in tissue taken 4 and 5 days post wounding. The tissue treated with AGE-coilagen consistently shows more mature appearing epidermis, with full granular and minimal overlying parakeratosis. The control sections, while almost completely epithelialized, still show poor granular layer formation and extensive overlying parakeratosis.
EXAMPLE 2
In this series of experiments, the healing properties of silk sutures reacted with sugar in order to produce AGEs were investigated. The following protocol was followed.
Rat Study Design:
Male Lewis rats (350-450 g) were made diabetic by intravenous injection of streptozotocin (65 mg/kg). One week later, they were bled, and their plasma tested for glucose levels. Rats with glucose levels greater than 400 mg/dl were considered diabetic. Diabetic and non-diabetic rats were then divided into groups:
TABLE A Unbrowned sutures Sutures browned with ribose
Normal Controls 5 5
Diabetics 5 5
Two lots of silk sutures (Davis and Geek, Danbury, CT) were tested; untreated sutures and AGE-modified sutures. AGE-modified sutures were prepared by incubating the sutures in 200 mM ribose in 100 mM phosphate buffer, pH 7.4 for 2 weeks. The sutures were rinsed in PBS prior to use. There were 5 normal control rats for each suture lot, and 5 diabetic rats for each lot, for a total of 20 rats. (See Table A, below)
For implantation of sutures, the rats were anesthetized using a mixture of Xylazine and Ketamine (1 :9), given intramuscularly at a level of .001 mg/g body weight. The backs of the rats were shaved, washed with soap and water, sprayed with alcohol, and swabbed with Provadine. An incision of approximately 5 cm was made in the skin along the midline of the back. A subcutaneous continuous stitch was used to close the incision, using the appropriate suture lot. The incision sites were visually inspected on a daily basis to monitor healing. The animals were sacrificed at 14 days using C02. The skin from their backs was removed, and evaluated visually as to how they have healed in comparison with the control groups.
The extent of wound closure was evaluated, blinded to group, by three individuals and graded on a scale of 1 + to 3+ with 1 + being the least healed and 3 + being the best closure with little or no scar. The degree of vascularization was evaluated by examination of the underlying skin using a light box. This enabled the investigator to visualize by transmitted light the amount of blood vessels formed along the suture line. Vascularity was evaluated on a 1 + to 4+ scale with 1 + being little vascularity around the incision site and 4 + being the greatest degree of vascularity. All animals were coded so that the final evaluations were done blinded as to the treatment group.
TABLE B
WOUND HEALING PROPERTIES OF AGE TREATED SUTURES OBSERVATIONS AT SACRIFICE
Figure imgf000021_0001
Closure
1 + = not healed well
2 + = healed well
3 + = healed very well; little or no scar
Vascularity
1 + = little or no vascularity around incision site
2 + = some vascularity around incision site
3 + = moderate vascularity around incision site
4 + = large amounts of vascularity around incision site
Rat # F had some pus oozing from incision TABLE C
SUMMARY OF WOUND HEALING DATA:
% of Rats in Each Category
Figure imgf000022_0001
Figure imgf000022_0002
EXAMPLE 3
Mouse Study Design
25 non-diabetic male C3H/Hej mice (25-30g) were anesthetized as described above. Their backs were shaved, washed with soap and water, sprayed with alcohol, and swabbed with Provadine. An incision of approximately 2-2.5 cm was made in the skin along the midline of the back. A cutaneous interrupted stitch was used to close the incision, using either control silk sutures or AGE-silk sutures (incubated with ribose as described in Example 2). The animals were sacrificed 7 days later and the skin removed as described above. The closure could not be evaluated adequately in mice due to the thin nature of the skin and the dark color of the strain being tested. Therefore, only the degree of vascularity was assessed as described above. One obvious but unexpected occurrence in this study was related to the degree of new hair growth in mice whose wounds were closed using AGE sutures. These results are included in Table D, below. TABLE D
WOUND HEALING PROPERTIES OF AGE SUTURES IN MICE
Animal Group Sutures Number of Mice in Each Category (% of Total) Number of Mice Vascularization" Showing An Increase in Hair
1 + 2 + 3 + 4 + Growth on Back
Normal Control 5 5 (33.3%) 3 (20%) 2 (13.3%) 1 (6.6%) Sutures (33.3%) (n = 15)
10 ro
Normal AGE-Sutures 0 (0%) 2 (20%) 4 (40%) 4 (40%) 7 (70%) (n = 10)
" See Table B for evaluation code
As indicated by the above data, the application of AGE to the skin in this fashion resulted in the promotion of hair growth. While the data shown is preliminary in nature, it clearly demonstrates this activity, and by virtue of its presence in an animal model that is considered credibly predictive of behavior in higher species, lends support to the application of the wound healing agents of the invention to this cosmetically constructive activity.
As indicated earlier, the agents herein may be formulated for the treatment of a variety of mammals, including domestic and farm animals, as well as humans, to control the wound healing process, and where desired, to assist in its promotion and the promotion of tissue growth and reconstruction as described and as evidenced hereinabove.
This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended Claims- and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

Claims

WHAT IS CLAIMED IS:
1. A method of treating wound healing dysfunction and/or promoting wound healing in mammals including humans, comprising administering to a mammal a therapeutically effective amount of a wound healing modulator comprising a material selected from the group consisting of an agent for enhancing wound healing, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
2. The method of Claim 1 wherein said agent is bound to a carrier.
3. The method of Claim 2 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
4. The method of Claim 1 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
5. The method of Claim 1 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
6. The method of Claim 1 wherein said wound healing modulator is selected from the group consisting of said agent, homologous agents derived from other cellular sources, homologous agents derived from other species, materials capable of promoting agent production and/or activity, materials capable of mimicking agent activity, muteins and fragments thereof, and mixtures thereof.
7. The method of Claim 1 wherein said binding partners to said agent are selected from the group consisting of anti-agent antibodies, a receptor for the agent, a material not antibody to the agent that antagonizes the production and/or wound healing modulating activity of the agent, and mixtures thereof.
8. The method of Claim 1 wherein said agent is derived from cells which are produced by recombinant DNA technologies.
9. The method of Claim 1 wherein said agent is administered in a concentration of at least about 100 ng/cm2 of wound area.
10. The method of Claim 1 wherein said agent is administered in a concentration of from about 1 μg to about 10 μg/cm2 of wound area.
1 1 . A pharmaceutical composition for the treatment of wound healing dysfunction and/or for promoting wound healing in mammals, including humans, comprising: A. a pharmaceutically effective amount of a wound healing modulator comprising a material selected from the group consisting of an agent for modulating wound healing, homologous agents derived from other cellular sources, homologous agents derived from other species, a material capable of promoting agent production and/or activity, a material capable of mimicking agent activity, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof; and B. a pharmaceutically acceptable carrier.
12. The composition of Claim 1 1 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
13. The composition of Claim 1 1 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
14. The composition of Claim 1 1 wherein said agent is present in an amount of at least about 100 ng dose.
15. The composition of Claim 1 1 wherein said agent is present in an amount of from about 1 μg/dose to about 10 μg/dose.
16. The composition of Claim 1 1 wherein said agent is derived from cells which are produced by genetic replication.
17. An antibody to an agent for modulating wound healing, wherein the agent to which said antibody is raised comprising is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
18. The antibody of Claim 17 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
19. The antibody of Claim 17 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
20. The antibody of Claims 1 7, 18 or 19 wherein said agent is derived from cells which are produced by genetic replication.
21. A method for detecting a disorder in wound healing in a mammal comprising measuring the activity of a wound healing modulator selected from the group consisting of an agent for modulating wound healing, homologous agents derived from other cellular sources, homologous agents derived from other species, a material capable of promoting agent production and/or activity, a material capable of mimicking agent activity, an anti-agent antibody, a receptor for the agent, a material not antibody to the agent that antagonizes the production and/or wound healing modulating activity of the agent, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof, said method for detecting comprising: A. preparing at least one sample of said agent; B. placing a detectable label on said agent sample; C. placing the labeled agent sample in contact with a tissue sample from a wound from said mammal in which disorder is suspected; and D. examining said tissue sample to locate said labeled material, and measuring to determine the activity of said agent.
22. The method of Claim 21 wherein said agent is bound to a carrier.
23. The method of Claim 22 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
24. The method of Claim 21 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
25. The method of Claim 21 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
26. The method of Claims 21 -24 or 25 wherein said agent is derived from cells which are produced by recombinant DNA technology.
27. A method for stimulating hair growth on a particular area of the body surface of a mammal comprising administering to said area an effective amount of a wound healing modulator, said wound healing modulator comprising a material selected from the group consisting of an agent for enhancing wound healing, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
28. The method of Claim 27 wherein said agent is bound to a carrier.
29. The method of Claim 28 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
30. The method of Claim 27 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
31. The method of Claim 27 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
32. A method for promoting host acceptance and incorporation of transplanted tissue and suture material comprising applying to said tissue and suture material an effective amount of a wound healing modulator, said wound healing modulator comprising a material selected from the group consisting of an agent for enhancing wound healing, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
33. The method of Claim 32 wherein said agent is bound to a carrier.
34. The method of Claim 33 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
35. The method of Claim 32 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, gIucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
36. The method of Claim 32 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
37. A prosthetic implant comprising a biocompatible material selected from organ tissue and synthetic suture material, said biocompatible material having applied thereto an effective amount of a wound healing modulator, said wound healing modulator comprising a material selected from the group consisting of an agent for enhancing wound healing, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
38. The prosthetic implant of Claim 37 wherein said agent is bound to a carrier.
39. The prosthetic implant of Claim 38 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio-compatible natural and synthetic resins, antigens, and mixtures thereof.
40. The prosthetic implant of Claim 37 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
41 . The prosthetic implant of Claim 37 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
PCT/US1993/001677 1992-02-25 1993-02-25 Method and agents for promoting wound healing WO1993016717A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84138392A 1992-02-25 1992-02-25
US07/841,383 1992-02-25

Publications (1)

Publication Number Publication Date
WO1993016717A1 true WO1993016717A1 (en) 1993-09-02

Family

ID=25284734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001677 WO1993016717A1 (en) 1992-02-25 1993-02-25 Method and agents for promoting wound healing

Country Status (2)

Country Link
AU (1) AU3733293A (en)
WO (1) WO1993016717A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6024688A (en) * 1996-03-08 2000-02-15 The Children's Medical Center Corporation Angiostatin fragments and method of use
WO2001091773A3 (en) * 2000-05-31 2002-05-02 Encelle Inc Method of stimulating hair growth
EP1319392A3 (en) * 2001-12-12 2003-08-27 Beiersdorf AG Melanine-forming hair dye
WO2010063678A3 (en) * 2008-12-01 2011-12-29 Henkel Ag & Co. Kgaa Novel deodorants and antiperspirants having hair growth inhibiting effect

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0157359A2 (en) * 1984-04-02 1985-10-09 National Jewish Hospital and Research Center Collagen matrix for tissue repair
EP0259893A2 (en) * 1986-09-12 1988-03-16 The Rockefeller University Agents for removing advanced glycosylation endproducts
WO1990000060A1 (en) * 1988-06-30 1990-01-11 Collagen Corporation Collagen wound healing matrices and process for their production
WO1993004086A1 (en) * 1991-08-23 1993-03-04 The Rockefeller University Receptors for advanced glycosylation endproducts and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0157359A2 (en) * 1984-04-02 1985-10-09 National Jewish Hospital and Research Center Collagen matrix for tissue repair
EP0259893A2 (en) * 1986-09-12 1988-03-16 The Rockefeller University Agents for removing advanced glycosylation endproducts
WO1990000060A1 (en) * 1988-06-30 1990-01-11 Collagen Corporation Collagen wound healing matrices and process for their production
WO1993004086A1 (en) * 1991-08-23 1993-03-04 The Rockefeller University Receptors for advanced glycosylation endproducts and uses thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024688A (en) * 1996-03-08 2000-02-15 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6521439B2 (en) 1996-03-08 2003-02-18 The Children's Medical Center Corporation Nucleic acids encoding plasminogen fragments
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
WO2001091773A3 (en) * 2000-05-31 2002-05-02 Encelle Inc Method of stimulating hair growth
US6992062B2 (en) 2000-05-31 2006-01-31 Encelle, Inc. Method of stimulation hair growth
US7700660B2 (en) 2000-05-31 2010-04-20 Encelle, Inc. Method of treating chronic ulcers
EP1319392A3 (en) * 2001-12-12 2003-08-27 Beiersdorf AG Melanine-forming hair dye
WO2010063678A3 (en) * 2008-12-01 2011-12-29 Henkel Ag & Co. Kgaa Novel deodorants and antiperspirants having hair growth inhibiting effect

Also Published As

Publication number Publication date
AU3733293A (en) 1993-09-13

Similar Documents

Publication Publication Date Title
Herndon et al. Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns
Hrynyk et al. Insulin and wound healing
DE69111919T2 (en) METHOD FOR SUPPRESSING THE ANGIOGENESIS OF TUMORS.
Nanney et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin
D'Amore Mechanisms of retinal and choroidal neovascularization.
DE69729125T2 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
CA2079585C (en) Ligand for the neu gene product
DE69629826T2 (en) THERAPEUTIC ANTIANGIOGENIC COMPOSITIONS AND METHODS
US5137875A (en) Hyaluronic acid-containing aqueous solution or aqueous dispersion of collagen
EP0579626A1 (en) Method and agents for promoting wound healing
AU654574B2 (en) Collagen film drug delivery for proteins
DE60029304T2 (en) ACTIVATION OF REGULATORY T CELLS THROUGH AN ALPHA MELANOCYTE STIMULATING HORMONE
US5616562A (en) Methods and compositions using substance P to promote wound healing
AU2004203732A1 (en) Uses of HMGB, HMGN, HMGA proteins
King Jr et al. Epidermal growth factor/transforming growth factor alpha receptors and psoriasis
Zhou et al. Hydrogels derived from acellular porcine corneal stroma enhance corneal wound healing
Hanneken et al. Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid.
US7837993B2 (en) Methods and compositions for regeneration of aged skeletal muscle tissues
WO1993016717A1 (en) Method and agents for promoting wound healing
Leibowitz et al. Effect of topically administered epidermal growth factor on corneal wound strength
JP2002542824A (en) Recombinant laminin 5
US6703363B1 (en) Recombinant laminin 5
Taherzadeh et al. Influence of human skin injury on regeneration of sensory neurons
CN111712253A (en) Neurotoxins to Minimize Scarring
CN110339345B (en) Recombinant human truncated keratinocyte growth factor-1 eye drops and preparation method and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载